Lanthanum carbonate adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Lanthanum carbonate
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Generic name
Class: Phosphate binder

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Drug reports received through 30 Jun 2026. Device reports have a separate cutoff, 30 Sep 2026. Why a report count is not a rate.

Reports on file

From April 2006 to June 2026, FDA received 645 adverse event reports that name Lanthanum carbonate. In these reports the drug is a suspect or interacting product.

In the same period, 637 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 89 reports in the 12 months to June 2026 and 74 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 89 (under 0.1%) name Lanthanum carbonate. Reports for patients 75 and over were 50.4% of the reports that name Lanthanum carbonate and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Lanthanum carbonate is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

The latest update of the FDA data, recorded on 28 Oct 2026, changed no count of this page.

In April to June 2026, FDA received 24 reports that name Lanthanum carbonate.
In January to March 2026, FDA received 29.
In April to June 2025, FDA received 14.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 118 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 615 of the 645 reports (95.3%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 118 terms.

Reaction terms in the reports that name Lanthanum carbonate, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 645 reports
Hyponatraemialow blood sodium	249	38.6%
General physical health deteriorationgeneral decline in health	244	37.8%
Multiple organ dysfunction syndromeseveral organs failing	242	37.5%
Abdominal distensiona bloated abdomen	237	36.7%
Sepsisa severe body-wide response to infection	236	36.6%
Stress	234	36.3%
Nauseafeeling sick	227	35.2%
Appendicitis	226	35%
Vomitingbeing sick	226	35%
Abdominal painstomach or belly pain	225	34.9%
Ascitesfluid in the abdomen	225	34.9%
Appendicolith	223	34.6%
Constipation	219	34%
Cardiogenic shockshock from the heart failing to pump	218	33.8%
Off label useused for a purpose or in a way not on the label	216	33.5%
Ventricular fibrillationa chaotic rhythm from the lower heart chambers	212	32.9%
Deaththe patient died; cause not stated by this term	191	29.6%
Condition aggravatedthe condition being treated got worse	171	26.5%
Somnolencedrowsiness	170	26.4%
Blood phosphorus increased	152	23.6%
Anaemialow red blood cells	146	22.6%
Dry mouth	146	22.6%
Myasthenia gravis	144	22.3%
Incorrect route of product administrationthe product was given by the wrong route	140	21.7%
Chronic obstructive pulmonary diseaseCOPD, a long-term lung disease	137	21.2%
Diabetes mellitusdiabetes	133	20.6%
Bacterial infectiona bacterial infection	132	20.5%
Intentional product misusedeliberate use not as intended	132	20.5%
Thrombosis	132	20.5%
Hyperphosphataemia	131	20.3%
Neuralgia	131	20.3%
Pulmonary embolisma blood clot in the lung	131	20.3%
Drug hypersensitivityan allergic-type reaction (the term names a medicine)	130	20.2%
Hypophosphataemia	127	19.7%
Swelling	126	19.5%
Drug intolerancethe medicine was not tolerated	125	19.4%
Blood cholesterol increasedraised cholesterol	123	19.1%
Sleep disordera sleep problem	118	18.3%
Blood uric acid increasedraised uric acid	115	17.8%
Sleep disorder therapy	107	16.6%
Dyspnoeashortness of breath	102	15.8%
Activated partial thromboplastin time prolonged	100	15.5%
Analgesic therapy	100	15.5%
Product use in unapproved indicationused for a purpose not on the label	100	15.5%
Drug ineffectivethe medicine did not work as expected	93	14.4%
End stage renal diseasekidney failure needing dialysis or transplant	93	14.4%
Gout	91	14.1%
Iron deficiency	91	14.1%
Ulcer	91	14.1%
Hyperlipidaemiaraised blood fats	89	13.8%

Download all 118 terms of Lanthanum carbonate (CSV)

The counts add to more than 645 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Same ingredient, other names

Reporters write a brand name or a generic name. Each name has its own page and its own count.

Names of Lanthanum carbonate with a page, in the order generic names, brand names, names as reported
Name	Name type	Reports
Lanthanum carbonate (this page)	Generic name	645
Fosrenol	Brand name	2,159

Sum of the separately reported names: 2,804. A report that names two of these names is in the sum two times. The sum is not the number of reports for the ingredient.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Lanthanum carbonate, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Congenital Anomaly/Birth Defect	Other Serious (Important Medical Events)	Not serious
2006	3	3	0	0	3	0	0	1	0
2007	0	0	0	0	0	0	0	0	0
2008	1	1	0	0	1	0	0	0	0
2009	1	1	0	0	1	0	0	0	0
2010	22	21	4	0	15	2	0	6	1
2011	29	28	9	3	17	3	0	6	1
2012	16	16	5	2	9	0	0	5	0
2013	0	0	0	0	0	0	0	0	0
2014	1	1	0	0	1	0	0	0	0
2015	3	3	0	0	2	0	0	1	0
2016	2	2	1	0	0	0	0	1	0
2017	27	20	1	0	19	0	0	18	7
2018	7	7	0	0	5	0	0	4	0
2019	8	7	0	0	2	0	0	5	1
2020	4	4	1	0	0	0	0	3	0
2021	75	74	63	1	7	0	0	62	1
2022	97	96	77	3	16	22	1	85	1
2023	99	98	80	41	62	54	2	91	1
2024	84	81	73	38	47	41	7	76	3
2025	75	74	65	42	49	46	33	70	1
2026	91	91	83	55	66	64	50	75	0

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Lanthanum carbonate, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Lanthanum carbonate, by the year in which FDA received them
Year	Reports
2006	3
2008	1
2009	1
2010	20
2011	31
2012	16
2014	2
2015	3
2016	2
2017	27
2018	8
2019	9
2020	5
2021	112
2022	91
2023	103
2024	97
2025	61
2026	53

Reports that name Lanthanum carbonate, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Lanthanum carbonate
Age	Reports	Share
Under 2	0	0%
2 to 11	0	0%
12 to 17	0	0%
18 to 44	14	2.2%
45 to 64	61	9.5%
65 to 74	65	10.1%
75 and over	325	50.4%
Age not given	180	27.9%

Sex of the patient in the reports that name Lanthanum carbonate
Sex	Reports	Share
Female	108	16.7%
Male	471	73%
Unknown or not given	66	10.2%

Type of reporter in the reports that name Lanthanum carbonate
Reporter	Reports	Share
Physician	62	9.6%
Pharmacist	6	0.9%
Other health professional	390	60.5%
Lawyer	0	0%
Consumer or non-health professional	185	28.7%
Not given	2	0.3%

Age and sex are as the report gives them. The reporter is the primary source in the report. 26.4% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Lanthanum carbonate record
Indication as recorded (MedDRA)	Reports	Share
Blood phosphorus increased	164	25.4%
Hyperphosphataemia	131	20.3%
Off label use	31	4.8%
Chronic kidney disease-mineral and bone disorder	3	0.5%
Chronic kidney disease	2	0.3%
End stage renal disease	2	0.3%

The reporter fills in the indication, and the field is often empty. Each share is of all 645 reports.

Drugs in the same reports

Other drugs that the reports of Lanthanum carbonate name, in any role, in order of name
Drug	Reports that name the two
Acetaminophen	275
Allopurinol	303
Calcitriol	263
Dextrose	259
Gabapentin	280
Ipratropium bromide	261
Lansoprazole	294
Melatonin	271
Metronidazole	287
Ondansetron	281

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Fosrenol same ingredient
Renvela same class
Sevelamer carbonate same class
Sevelamer hydrochloride same class
Lantarel next in the A to Z list
Lantus next in the A to Z list
Lansoprazole next in the A to Z list
Lantus Solostar next in the A to Z list
Lanreotide acetate next in the A to Z list
Lapatinib next in the A to Z list
Lanreotide next in the A to Z list
Lapenax next in the A to Z list

These links are for navigation. No count selected them. The class page lists each drug of the class.

Official pages

DailyMed labels for Lanthanum carbonateThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Lanthanum carbonate: adverse event reports that FDA received. https://reportedreactions.com/drug/lanthanum-carbonate/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Lanthanum carbonate as a suspect or interacting product. The 637 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Lanthanum carbonate was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Lanthanum carbonate?

No. It is a count of what people reported to FDA: 645 reports from April 2006 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Other health professional (60.5%), consumer or non-health professional (28.7%) and physician (9.6%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page